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Inflammatory Bowel Disease (IBD) is a chronic inflammatory condition in the colon that includes
ulcerative colitis and Crohn’s disease. Dexamethasone is a steroid anti-inflammatory drug that can
be used in IBD therapy. This study aims to obtain an optimum formulation of a dexamethasone drug
delivery system for IBD treatment and to investigate its release profile based on an in vitro dissolution
test. Dexamethasone was formulated as a double-coated tablet in combination with a probiotic L.
acidophilus and B. longum mixture (1:1). The core tablets were produced using the wet granulation
method, after which they were coated with pectin 4% b/v on the inner coat and a mixture of Eudragit
L100 and S100 (1:4) on the outer coat. Three different core tablet formulas were prepared by varying
the concentration of probiotics at 0%, 16% and 40% (F1, F2, and F3, respectively). The cumulative
drug release of F1, F2 and F3 in HCl 0.1 N pH 1.2 for 2 hours were 42.92 ± 1.55%, 39.41 ± 4.10%,
and 39.39 ± 1.63%, respectively, while in the phosphate buffer pH 6.8 they were 102.83 ± 1.56%,
105.08 ± 1.70%, and 98.81 ± 3.37% respectively, after 12 hours. From the results, we conclude that
all formulas could be promising candidates for developing colon-targeted drug delivery.
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INTRODUCTION
Inflammatory bowel disease (IBD) is a chronic
inflammatory condition divided into ulcerative colitis
and Crohn’s disease (Crowley & Muise, 2018). In
2017, the prevalence of IBD in the world reached 6.8
million cases (Alatab et al., 2020). From 2011 to 2013,
the average number of IBD incidents in Indonesia went
0.77 cases per 100,000 population, with ulcerative colitis
representing 0.49 cases and Crohn’s disease 0.27 cases
(Ng et al., 2019).
One of the active substances used in the treatment of IBD
is dexamethasone, a corticosteroid drug commonly used
to treat mild to severe cases (Oshi et al., 2018). It has a
high anti-inflammatory potential and a long duration of
action compared to other glucocorticoid drugs. However,
peroral administration of the drug can cause systemic
side effects, such as hyperglycemia, hypertension and
osteoporosis (Zeng et al., 2016). To minimise systemic
absorption and to increase treatment locally in the colon,
colon-targeted drug delivery systems have been widely
investigated (Amidon et al., 2015; Iswandana et al.,
2018; Iswandana et al., 2017).
One of the strategies developed for colon-targeted delivery
systems is the double layer-coated tablet system. Such
a system involves tablets coated with a primary (inner)
and a secondary (outer) layer. The outer layer consists of

pH-sensitive polymers, which will dissolve depending
on the pH of the dissolution medium. The inner layer
consists of polymers, such as polysaccharides, which can
be degraded by colon microflora, allowing the release of
drugs into the colon (Prudhviraj et al., 2015). Previously,
the polymers used for colon-targeted drug delivery
systems have included alginate/polyvinyl alcohol and
alginate-carboxymethyl cellulose (Iswandana et al.,
2018); alginate/hydroxypropyl methylcellulose and
alginate–chitosan (Iswandana et al., 2018); and chitosan
tripolyphosphate (Iswandana et al., 2017).
One of the polysaccharides that is commonly used in
drug delivery is pectin. This is non-toxic, biodegradable,
biocompatible, and perfectly degraded by microflora
enzymes, making it suitable for a colon- targeted
delivery system. Furthermore, it has a long retention
time in the gastrointestinal (GI) tract. However, pectin
has limitations because of its high solubility and because
it can swell in an aqueous medium. It is therefore less
effective in preventing drug release in the upper GI tract
(Maestrelli et al., 2007). Therefore, core tablets coated
with polysaccharides are normally re-coated with enteric
polymers. This strategy is used to minimise the release
of the drug into the upper GI tract before it arrives in
the colon. Enteric polymer that are commonly used
are Eudragit L100 and Eudragit S100. Eudragit L100
is dissolved at a pH above 6, while Eudragit S100 is
dissolved at one above 7 (Thakral et al., 2013).
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In a delivery system based on microflora activity, the
number of colon microflora must be sufficient to digest
polysaccharides in order for the drug to be released
into the colon in appropriate quantities. However,
some conditions, such as variations in the number of
colon microflora between individuals, reduce microbial
numbers due to antibiotic use, and the slow process of
enzyme degradation inhibits the release of drugs in the
colon (Pooja et al., 2011). In addition, ulcerative colitis
is always accompanied by an imbalance of microflora
in the colon (Kaur et al., 2016). These barriers can be
overcome by adding probiotics in different preparations
or as excipients in tablet formulations (Ghosh et al.,
2010). The addition of probiotics has the advantage of
facilitating the release of drugs in the colon. In addition,
the process is also more efficient, since probiotics and
active substances can be co-delivered in a single dosage
form.

Preparation of Core Tablets Using the Wet
Granulation Method
Core tablets were prepared according to the formula
shown in Table 1. L. acidophilus and B. longum were
mixed homogeneously. Half of the probiotic mixture was
then mixed with Avicel® PH 102 and dexamethasone
until homogenous. A 9% w/w PVP solution was added,
and the mixture blended until a homogenous wet mass
was formed; it was then sieved through an 8-mesh sieve
to produce damp granules. The moist granules were then
dried in an oven at a temperature of 40°C for 2 hours.
Subsequently, the dried granules were sifted through an
18-mesh sieve and mixed with the rest of the probiotics,
magnesium stearate, and talc. The final granules were
then evaluated for their compressibility index, Hausner
ratio, repose angle, flow rate (g/second), and moisture
content before compression using an Erweka EP-1
(Germany) single-punch tableting machine.

Probiotics are known to mimic colon microflora by
producing enzymes that can degrade polysaccharides.
The genus Lactobacillus and Bifidobacterium have
been reported to degrade pectin (Singh et al., 2015).
Additionally, the probiotics L. acidophilus and B. longum
have shown clinical effects as anti-inflammatories (SaezLara et al., 2014). This study aims to formulate a doublelayer coated tablet containing dexamethasone and to
obtain an optimum concentration of probiotics that can
enhance the release of dexamethasone into the colon.
Double-coated dexamethasone tablet formulations were
prepared by incorporating probiotics into the core tablet.
Three formulas were formulated, containing 0%, 16%
and 40% probiotics, to study their effect on the drug
release profile. Pectin was used as the inner coat layer,
and a mixture of Eudragit L100 and Eudragit S100 as the
outer coat layer.

Table 1. Formulation of the core tablet

MATERIALS AND METHODS
The materials used were dexamethasone (Lloyd,
Indonesia), dexamethasone BPFI (BPOM, Indonesia),
pectin with a degree of esterification of 71% (Danisco,
USA), Avicel® PH 102 (Brataco, Indonesia), PVP
K-30 (BASF, Germany), talc (Brataco, Indonesia),
magnesium stearate (Brataco, Indonesia), L. acidophilus
(Shandong Zhongke Jiayi Bioengineering, China), B.
longum (Shandong Zhongke Jiayi Bioengineering,
China), Eudragit® L100 (Evonik, Germany), Eudragit®
S100 (Evonik, Germany), ethanol (RIV Chemicals,
Indonesia), isopropyl alcohol (Brataco, Indonesia),
triethyl citrate (Jinan Jinbang Chemical, China),
hydrochloric acid (Merck, Germany), sodium hydroxide
(Merck, Germany), potassium dihydrogen phosphate
(Merck, Germany), and aquadest (Brataco, Indonesia).

Composition
Dexamethasone
L. acidophilus
B. longum
Avicel® PH 102
PVP
Talk
Magnesium stearate

Amount per tablet (mg)
F1

F2

F3

0.5
93.5
5.9
4
2

0.5
8
8
77.5
5.8
4
2

0.5
20
20
53.5
5.9
4
2

Tablet Coating with Pectin
The coating solution was prepared by dissolving 4
g pectin in 100 ml aquadest. 1.4 g triethyl citrate was
added to the solution and stirred until homogeneous
(Table 2). The tablets were coated using a coating pan
(Erweka DKM, Germany) equipped with a spray gun
(Meiji F-75G, Japan) at a speed of 18 rpm.
Tablet Coating with Eudragit L100 and Eudragit
S100
Eudragit L100 and Eudragit S100 (1:4) were dissolved
in 100 mL of isopropyl alcohol to make a 10% w/v
solution. Triethyl citrate 20% w/w was added to the
coating solution and stirred until homogeneous. The
second coating formula can be seen in Table 2. The
tablets were coated in the same conditions and using the
same methods as the inner coating. The tablets were also
coated using a coating pan (Erweka DKM, Germany)
equipped with a spray gun (Meiji F-75G, Japan) at a
speed of 18 rpm.
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Table 2. Formulation of coating solution
Composition

Amount

Inner layer
Pectin
Triethyl citrate
Aquadest
Outer layer

4g
1.4 g
up to 100 ml

Eudagrit® L100
Eudagrit® S100
Triethyl citrate
Aquadest

2g
8g
2g
up to 100 ml

Dexamethasone in Tablet Assay
A total of 20 tablets were weighed, then pulverized.
The powder equivalent to 1.4 mg of dexamethasone
was weighed, then dissolved in the ethanol-water
mixture (2:1) in a 100 ml volumetric flask, followed
by sonication for 10 minutes. The solution was then
filtered with a membrane filter (pore size 0.45 μm).
Subsequently, sample absorbance was measured using a
spectrophotometer UV-Vis (Shimadzu UV-1800, Japan)
at λmax 240 nm.
A calibration curve was made using dexamethasone
BPFI. 10 mg of dexamethasone BPFI was weighed
and dissolved in an ethanol-water mixture (2:1) in a 100
ml volumetric flask to create a 100 μg/ml solution. This
solution was then diluted to obtain a series of solutions
with concentrations of 6, 8, 10, 12, 14, 16 and 18 μg/ml.
Each solution was then measured in a spectrophotometer
UV-Vis at λmax 240 nm.
Tablet Evaluation
Organoleptic tests were performed by observing shape,
size, colour, odour, surface, and physical defects. The
surface morphology of the tablets was observed using
scanning electron microscopy (Jeol JSM-5310 LV,
Japan). The tablet dimension was measured using a
vernier caliper.
A weight uniformity test was conducted by weighing ten
tablets one by one and calculating their average weight.
The dexamethasone content per tablet was calculated
and expressed in the percentage of the amount of
dexamethasone added to the formulation. A friability test
was performed in a friability tester apparatus (Vanguard
Pharmaceutical Machinery LIC-2, USA), using 20
tablets at a speed of 25 rpm for 4 minutes. In addition,
a hardness test was performed on ten tablets using a
hardness tester (Erweka TBH 28, Germany).
Disintegration Time
Tablet disintegration time was investigated using
E-ISSN 2477-0612
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a disintegration tester apparatus (Electrolab ED-2,
India) in an artificial gastric fluid LP (HCl pH 1.2) at
a temperature of 37±2°C. The disintegration time was
also investigated in a simulated intestinal fluid medium
(phosphate buffer pH 6.8) at a temperature of 37±2°C.
In Vitro Dissolution Test
An in vitro dissolution test was performed using three
tablets from each formula in an apparatus 1 (basket)
dissolution tester (Electrolab TDT-08L, India), at a speed
of 100 rpm and temperature of 37°±0.5°C. The test was
conducted in 500 ml hydrochloric acid 0.1 N for the first
two hours. After two hours, the medium was replaced
with 500 ml phosphate buffer pH 7.2, and the test
continued for three hours. After this time, the medium
was replaced with 500 ml phosphate buffer pH 6.8, and
the test continued for another 7 hours. The phosphate
buffer pH 6.8 was heated for 30 minutes and purged
with CO2 for 30 minutes before use to create anaerobic
conditions.
An amount of 5 ml of the samples was withdrawn at
predetermined time intervals. Each sample was filtered
with a 0.45 μm membrane filter before analysis with a
spectrophotometer UV-Vis. After each sampling, 5 ml of
new dissolution medium was added.
RESULTS AND DISCUSSION
Preparation of Double Layer-Coated Tablets
As mentioned previously, the core tablets were prepared
by varying the concentration of probiotics in them. Half
of the probiotics were added to the wet granulation to
ensure their homogeneity, and the rest were added to
the dried granules as the external phase. The granules
from the three formulas demonstrated excellent flow
characteristics based on the compressibility index,
Hausner ratio, and angle of repose (Table 3). These
results indicate that although half of the probiotics
were added as an external phase, this did not negatively
affect the flow characteristics of the granules. Good
flow characteristics, which are represented by a low
compressibility index and Hausner ratio, were also
supported by a low moisture content of below 5%,
since high moisture content can negatively influence the
characteristics.
The core tablets from all three formulas were white,
round with biconvex surfaces, smooth and shiny (Figure
1). Pectin-coated tablets of all formulas also had similar
shapes and a yellowish colour. The distinctive colour of
pectin probably produced this effect. The double layercoated tablets were also round, with biconvex surfaces
with a yellowish tint. Evaluation of the tablet surface
morphology with SEM showed that the whole surface
of the core tablets was covered by the coating layer
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Table 3. Evaluation of tablet granules
Parameters
Compressibility index
Hausner ratio
Angle of repose (°)

F1
11.48 ± 2.12
1.13 ± 0.03
25.56 ± 1.38

F2
14.15 ± 0.80
1.16 ± 0.01
27.30 ± 0.69

F3
9.26 ± 2.17
1.10 ± 0.03
26.18 ± 1.85

Figure 1. Appearance of the core tablets F1 (a); F2 (b); F3 (c); pectincoated tablets F1 (d); F2 (e); F3 (f); and of the double layer-coated
tablets F1 (g); F2 (h); and F3 (i).
(Figure 2). However, the texture of the coating layer
appeared bumpy, with pores which might have been due
to the tablet sticking during the second coating process.
The results of the drug assay showed that the
dexamethasone content in tablets F1, F2, and F3 was
between 90% and 110% (Table 4). These results align
with the Indonesian Pharmacopeia requirements for
dexamethasone tablet assay. The thickness and diameter
were measured for the core tablets, tablets with an inner
coat, and those with a double coat. As shown in Table 4,
the thickness of the tablets after the first coating showed
increases of 7.61%, 5.74% and 4.84%, while the diameter
after the first coating showed increases of 2.10%, 2.52%
and 2.54% for F1, F2 and F3 respectively. These results
indicate that the coating layers were distributed more on
the upper and lower surfaces of the tablets, rather than
on the side. Similar results were found after the second
coating. Among the three formulas, F1 showed the
highest increase in thickness, followed by F3 and F2.

The highest increase in weight was also shown by F1, in
line with the increase in thickness. However, despite the
higher gain in diameter shown by F3 compared to F2,
F3 showed a lower increase in weight. This is probably
because the density of the coating layers on F3 were less
than those on F2.
The hardness of the core tablets from the three formulas
was found to be similar, between 5-6 kPa (Table 5). The
coated tablets showed increased hardness, probably
due to the flexibility of the film layer surrounding
them. These results meet the optimum criteria of tablet
hardness, which are > 4 kP for the core tablet and 10-20
kP for a coated tablet (Allen et al., 2011). The friability of
the core tablets from all formulations was less than 0.2%
(Table 5), indicating good mechanical characteristics.
This value ensures the mechanical strength of the tablets
in withstanding the pressure exerted during the coating
process. After coating, the friability was even lower for
all formulas, possibly due to the compact coating layer.
E-ISSN 2477-0612
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Figure 2. Morphology of the surface of the core tablets and
double layer-coated tablets F1 (a and d), F2 (b and e), and F3 (c
and f), shown by SEM with 1000 times magnification.
Table 4. Characteristics of the double layer-coated dexamethasone tablets
Increase in
thickness
(%)

Tablet
Diameter
(mm)

Increase in
diameter
(%)

3.02 ± 0.03
3.25 ± 0.03
3.58 ± 0.06

7.61
10.15

7.13 ± 0.04
7.28 ± 0.03
7.42 ± 0.05

2.10
1.92

103.29 ± 1.43
112.23 ± 1.47
119.79 ± 1.17

8.65
6.74

98.42 ± 0.57

3.31 ± 0.03
3.50 ± 0.04
3.76 ± 0.06

5.74
7.43

7.13 ± 0.04
7.31 ± 0.04
7.49 ± 0.06

2.52
2.46

106.57 ± 1.91
115.66 ± 1.78
122.59 ± 1.85

8.53
6.50

101.21 ± 0.69

3.08 ± 0.05
3.23 ± 0.05
3.59 ± 0.07

4.87
11.14

7.07 ± 0.04
7.25 ± 0.02
7.33 ± 0.06

2.54
1.10

105.82 ± 2.11
112.86 ± 1.62
120.39 ± 1.36

6.65
6.67

Formula

Tablet
Components

Drug
Content (%)

Thickness
(mm)

F1

Core tablet
+inner coat
+outer coat

99.55 ± 1.60

F2

Core tablet
+inner coat
+outer coat

F3

Core tablet
+inner coat
+outer coat

Average Weight
(mg)

Table 5. Evaluation of tablet hardness and friability
Formula

Tablet

Hardness (kP)

Friability (%)

F1

Core tablet
Double layer-coated tablet
Core tablet
Double layer-coated tablet
Core tablet
Double layer-coated tablet

5.22 ± 0.46
13.14 ± 1.99
5.01 ± 1.26
16.36 ± 1.52
6.01 ± 0.65
15.80 ± 3.07

0.229
0.022
0.165
0.061
0.102
0.072

F2
F3
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Figure 3. Cumulative drug release of F1, F2 and F3 in different media
(mean ± SD, n=3).
The outer layer of
the coating consisted
of
Eudragit® L100 and Eudragit® L100. Eudragit® is a
polymethacrylate-based copolymer with carboxylic
acid as the pendant group. The carboxylic groups are
insoluble in an acidic environment and were therefore
expected to protect the tablet from disintegration
in the stomach. All of the formulas showed that no
disintegration occurred in the pH 1.2 medium, indicating
that the coating layer could protect the core tablets from
vigorous water infiltration. The tablet dissolution test
showed cumulative drug releases of around 39%, 43%
and 39% for F1, F2 and F3 respectively in the pH 1.2
medium for the first two hours (Figure 3). This high
percentage of drug release is probably because the layer
was not thick enough.
As the tablet travels from the stomach to the intestine
(pH 7.2), the Eudagrit® layer will dissolve. Therefore,
we added pectin with a degree of esterification of 71%
as an inner layer for extra protection. Pectin with a high
degree of esterification is less soluble in basic medium
and was thus expected to retain the drug release in the
intestine. The dissolution test for all the formulas in the
phosphate buffer medium pH 7.2 for 3 hours showed
around a 30% increase in cumulative drug release since
exposure to pH 1.2 (Figure 3). This means around 60%
of drugs had been released since 0h.
Pectin is a polysaccharide that can be degraded by
pectinase, an enzyme available in the colon. Therefore,
we expected that the pectin layer would be degraded
in the colon, allowing the tablet to disintegrate and
release the rest of the drugs. We also added probiotics
in the tablet formulas to assist the disintegration process.
When the dissolution test was continued to phosphate
buffer pH 6.8, which represents the pH of the colon, the

total cumulative drug release after 7 hours was 98.81 ±
3.37%, 102.83 ± 1.56%, and 105.08 ± 1.70% for F1, F2,
and F3 respectively. These results suggest that increased
probiotic concentration in the tablet could slightly
increase the cumulative drug release.
CONCLUSION
We successfully prepared a double layer-coated
dexamethasone tablet containing probiotics. Although
the drug release in the pH 1.2 and pH 7.2 medium was
high, all the formulae could be promising candidates
for developing colon-targeted drug delivery. Further
optimisation of the coating layer and probiotic
concentration are essential to obtain the best drug release
profile.
ACKNOWLEDGMENT
The authors thank Universitas Indonesia for funding
this research through PUTI Grant with contract number
NKB-1808/UN2.RST/HKP.05.00/2020.
CONFLICT OF INTEREST
The authors declared no conflict of interest
REFERENCES
Alatab, S., Sepanlou, S. G., Ikuta, K., Vahedi, H.,
Bisignano, C., Safiri, S., & Naghavi, M. (2020). The
global, regional, and national burden of inflammatory
bowel disease in 195 countries and territories, 1990–
2017: a systematic analysis for the Global Burden of
Disease Study 2017. The Lancet Gastroenterology &
Hepatology, 5(1), 17-30.
E-ISSN 2477-0612

138

Pharm Sci Res, Vol 9 No 3, 2022

Allen, L. V., Popovich, N. G., & Ansel, H. C. (2011).
Ansel’s Pharmaceutical Dosage Forms and Drug
Delivery Systems (9th ed.). Philadelphia: Lippincott
Williams & Wilkins.
Amidon, S., Brown, J. E., & Dave, F. S. (2015). Colontargeted oral drug delivery system: design trends and
approaches. AAPS PharmSciTech, 16(4), 731-741.
Crowley, E., & Muise, A. (2018). Inflammatory bowel
disease: what very early onset disease teaches us.
Gastroenterology Clinic of North America, 47(4), 755772.
Ghosh, P. K., Gupta, V. B., Gondoliya, B., & Rathore,
M. S. (2010). Probiotic-assisted colon-spesific delivery
of diclofenac sodium from guar gum matrix tablets: in
vitro evaluation. Asian Journal of Pharmaceutics, 4(4),
173-178.
Iswandana, R., Amangkoe, E., & Isnaini, R. (2018).
Tetrandrine beads using alginate/polyvinyl alcohol and
alginate-carboxymethyl cellulose: Not ideal as colontargeted dosage form. Journal of Pharmaceutical
Negative Results, 9(1), 14-20.
Iswandana, R., Mutia, M. P., & Widyaningrum, F.
K. (2018). Unsuccessful delivery of tetrandrine from
colon-targeted dosage forms comprising alginate/
hydroxypropyl methylcellulose and alginate–chitosan
beads. International Journal of Applied Pharmaceutics,
10(Special Issue 1), 396-402.
Iswandana, R., Putri, K. S., Dwiputra, R., Yanuari,
T., Sari, S. P., & Djajadisastra, J. (2017). Formulation
of chitosan tripolyphosphate-tetrandrine beads using
ionic gelation method: In vitro and in vivo evaluation.
International Journal of Applied Pharmaceutics, 9(5),
109-115.
Iswandana, R., Putri, K. S., Sandiata, C. E., Triani,
S., Sari, S. P., & Djajadisastra, J. (2017). Formulation
of tetrandrine beads using ionic gelation method Capectinate coated pH-sensitive polymers as colontargeted dosage form. Asian Journal of Pharmaceutical
and Clinical Research, 10(10), 90-95.
Iswandana, R., Putri, K. S., Wulandari, F. R., Najuda,
G., Sari, S. P., & Djajadisastra, J. (2018). Preparation of
calcium alginate-tetrandrine beads using ionic gelation
method as colon-targeted dosage form. Journal of
Applied Pharmaceutical Science, 8(5), 68-74.
Kaur, R., Gulati, M., & Singh, S. K. (2016). Role of
synbiotics in polysaccharide assisted colon targeted
microspheres of mesalamine for the treatment of
E-ISSN 2477-0612

Sagita, et al.

ulcerative colitis. International Journal of Biological
Macromolecules, 95, 438-450
Maestrelli, F., Cirri, M., Corti, G., Mennini, N., &
Mura, P. (2007). Development of enteric-coated
calcium pectinate microspheres intended for colonic
drug delivery. European Journal of Pharmaceutics and
Biopharmaceutics, 69, 508-518.
Ng, S. C., Kaplan, G. G., Tang, W., Banerjee, R.,
Adigopula, B., & Sung, J. Y. (2019). Population density
and risk of inflammatory bowel disease: a prospective
population-based study in 13 countries or regions in
Asia-Pacific. The American Journal of Gastroenterology,
114(1), 107–115.
Oshi, M. A., Naeem, M., Bae, J., Kim, J., Lee, J., & Yoo,
J. (2018). Colon-targeted dexamethasone microcrystals
with
pH-sensitive
chitosan/alginate/Eudragit
S
multilayers for the treatment of inflammatory bowel
disease. Carbohydrate Polymers, 198, 434-442.
Pooja, C., Naveen, M., Rathore, M. S., Jain, A., &
Kumar, J. A. (2011). Probiotic assisted colon targeted
drug delivery system: research scope. Asian Journal of
Pharmaceutical and Clinical Research, 4, 12-15.
Prudhviraj, G., Vaidya, Y., Singh, S. K., Yadav, A. K.,
Kaur, P., Gulti, M., & Gowthamarajan, K. (2015). Effect
of co-administration of probiotics with polysaccharide
based colon targeted delivery systems to optimize site
specific drug release. Europan Journal of Pharmaceutics
and Biopharmaceutics, 97, 164-172.
Saez-Lara, M. J., Gomez-Llorente, C., Plaza-Diaz, J., &
Gil, A. (2014). The role of probiotic lactic acid bacteria
and bifidobacteria in the prevention and treatment of
inflammatory bowel disease and other related diseases:
a systematic review of randomized human clinical trial.
BioMed Research International, 1-15.
Singh, S. K., Yadav, A. K., Prudhviraj, G., Gulati, M.,
Kaur, P., & Vaidya, Y. (2015). A novel dissolution
method for evaluation of polysaccharide based colon
spesific delivery system: a suitable alternative to animal
sacrifice. Europan Journal of Pharmaceutical Science,
73, 72-80.
Thakral, S., Thakral, N. K., & Majumdar, D. K. (2013).
Eudragit®: a technology evaluation. Expert Opinion
Drug Delivery, 10(1), 131-149.
Zeng, A., Dong, K., Wang, M., Sun, J., Dong, Y.,
Wang, K., & Xing, J. (2016). Investigation of the
colon-targeting, improvement on the side-effects and
therapy on the experimental colitis in mouse of a resin
microcapsule loading dexamethasone sodium phosphate.
Drug Delivery, 23(6), 1992-2002.

